Metabolomics During ElectroConvulsivoTherapy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorHôpital le Vinatier
About this trial
Investigators will measure the variation of blood Metabolome through 1H NMR at several time points during the course of electroconvulsivetherapy in patients with a major depressive episode. Patients with a major depressive disorder or a bipolar disorder and a current major depressive episode will be included in this study. Investigators hypothesized that Metabolome could be a source to predict response during ECT and to help understanding underlying biological mechanisms.
Eligibility criteria
Qualifiers
Major depressive episode according to DSM-5 criteria
Diagnosis of major depressive disorder or bipolar disorder
MADRS score >22
having given written, free and informed consent
Disqualifiers
whose consent is not admissible or who refuse to participate in the study
deprived of liberty by judicial or administrative decision
For which there is a particular risk contraindicating the cure of ECT
Suffering from schizophrenia spectrum disorders or persistent delusional disorder as described by DSM-5 Criterion D for Major Depressive Disorder
Trial design
Treatments tested in this trial
- Electroconvulsive therapy
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov